0000000000343552

AUTHOR

Gianluca Aimaretti

showing 2 related works from this author

Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study

2018

AimsType 2 diabetes (T2D) accelerates the decline in glomerular function; however, some individuals do not develop chronic kidney disease despite advanced age and long-lasting T2D. We aimed to phenotype patients with T2D aged 80years or older who presented with a fully preserved kidney function.MethodsFrom an Italian population of 281,217 T2D outpatients, we collected data on demographics, anthropometrics, diabetes duration, HbA1c, fasting plasma glucose, lipids, liver enzymes, estimated glomerular filtration rate (eGFR), albumin excretion rate (AER), chronic complications, and medication use. We primarily compared patients with a fully preserved kidney function (eGFR>90ml/min/1.73m(2) and …

MaleEpidemiologyEndocrinology Diabetes and MetabolismType 2 diabetes030204 cardiovascular system & hematologyKidneyType 2 diabeteSettore MED/13 - Endocrinologia0302 clinical medicineEndocrinology80 and overMedicineDiabetic Nephropathies030212 general & internal medicineAged 80 and overeducation.field_of_studyType 2 diabetesGeneral MedicineEpidemiology; Insulin resistance; Nephropathy; Protective; Type 2 diabetesDiabetes and MetabolismPhenotypeLipotoxicityFemaleType 2HumanGlomerular Filtration Ratemedicine.medical_specialtyPopulationRenal functionEpidemiology; Insulin resistance; Nephropathy; Protective; Type 2 diabetes; Internal Medicine; Endocrinology Diabetes and Metabolism; EndocrinologyNephropathyEpidemiology; Insulin resistance; Nephropathy; Protective; Type 2 diabetes; Aged 80 and over; Diabetes Mellitus Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Phenotype; Internal Medicine; Endocrinology Diabetes and Metabolism; Endocrinology03 medical and health sciencesInsulin resistanceInternal medicineDiabetes mellitusDiabetes MellitusInternal MedicineHumanseducationAgedbusiness.industryInsulin resistancemedicine.diseaseNephropathyProtectiveDiabetes Mellitus Type 2Diabetic NephropathiebusinessKidney disease
researchProduct

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial …

2015

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population …

Malemedicine.medical_specialtyAcute coronary syndromePopulationLIXisenatide610 Medicine & healthHypoglycemiaPlacebop38 Mitogen-Activated Protein Kinases11171 Cardiocentro Ticino2705 Cardiology and Cardiovascular Medicinelaw.inventionSettore MED/13 - EndocrinologiaAcute Coronary Syndrome; Aged; Cardiovascular Diseases; Double-Blind Method; Female; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Peptides; Placebos; Protein Kinase Inhibitors; Research Design; p38 Mitogen-Activated Protein Kinases; Cardiology and Cardiovascular MedicinePlacebosLixisenatidechemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawGlucagon-Like Peptide 1Internal medicineJournal ArticlemedicineHumansComparative StudyMyocardial infarctionAcute Coronary SyndromeeducationProtein Kinase InhibitorsAgededucation.field_of_studybusiness.industryUnstable anginaResearch Support Non-U.S. Gov'tta3121Middle Agedmedicine.diseaseSurgeryMulticenter StudychemistryCardiovascular DiseasesResearch DesignRandomized Controlled TrialCardiologyFemaleCardiology and Cardiovascular MedicinebusinessPeptides
researchProduct